Literature DB >> 20307515

Modulation of PPAR-gamma by telmisartan protects the heart against myocardial infarction in experimental diabetes.

Sameer Goyal1, Sachin Arora, Tarun Kumar Bhatt, Prasenjit Das, Amit Sharma, Santosh Kumari, Dharamvir Singh Arya.   

Abstract

Telmisartan, an angiotensin II-receptor blocker (ARB), is a partial agonist of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma). We investigated whether telmisartan improved the pathophysiology of myocardial infarction in diabetes partially through the PPAR-gamma pathway by assessing a variety of indices, e.g., hemodynamic, biochemical, histoarchitectural changes, and apoptosis. Diabetes was induced by a single dose of streptozotocin (70 mg/kg, IP). Diabetic rats received either telmisartan (10 mg/kg/day, orally), the PPAR-gamma antagonist GW9662 (1 mg/kg/day, IP), or both for 14 days with concurrent administration of isoproterenol (85 mg/kg, SC) on days 13 and 14. Compared with diabetic controls, diabetic rats with myocardial infarction exhibited altered hemodynamic profiles and reduction in the activities of creatine kinase-MB isoenzyme, lactate dehydrogenase, superoxide dismutase, catalase, and glutathione level along with increased level of malondialdehyde in the heart. Further, diabetic animals with myocardial infarction exhibited increased myonecrosis, edema, and apoptotic cell death. Treatment with telmisartan significantly improved the redox status of the myocardium with subsequent cardiac functional recovery. However, significant effects were lowered in animals treated with telmisartan plus GW9662. Telmisartan markedly inhibited Bax expression, TUNEL-positive cells, myonecrosis, and edema. On the other hand, administration of telmisartan plus GW9662 did not elicit the same effects, nor did they increase Bcl-2 protein expression in isoproterenol-induced myocardially infarcted diabetic rats when administered concomitantly or individually. Moreover, down-regulated PPAR-gamma expression in myocardially infarcted diabetic hearts was increased by telmisartan treatment. In addition to class effects of ARBs, telmisartan reduces oxidative stress and apoptosis and improves cardiac function via the PPAR-gamma pathway. Copyright 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20307515     DOI: 10.1016/j.cbi.2010.03.030

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  14 in total

1.  Telmisartan protects against insulin resistance by attenuating inflammatory response in rats.

Authors:  Xizhen Xu; Xiaoming Yin; Wenjing Feng; Geng Li; Daowen Wang; Ling Tu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2011-06-14

2.  CYP2J2 attenuates metabolic dysfunction in diabetic mice by reducing hepatic inflammation via the PPARγ.

Authors:  Rui Li; Xizhen Xu; Chen Chen; Yan Wang; Artiom Gruzdev; Darryl C Zeldin; Dao Wen Wang
Journal:  Am J Physiol Endocrinol Metab       Date:  2014-11-11       Impact factor: 4.310

3.  Curcumin attenuates cardiac fibrosis in spontaneously hypertensive rats through PPAR-γ activation.

Authors:  Zhe Meng; Xin-hui Yu; Jun Chen; Ling Li; Sheng Li
Journal:  Acta Pharmacol Sin       Date:  2014-08-18       Impact factor: 6.150

4.  PPARα/γ antagonists reverse the ameliorative effects of osthole on hepatic lipid metabolism and inflammatory response in steatohepatitic rats.

Authors:  Xi Zhao; Feng Wang; Ruijun Zhou; Zengyan Zhu; Meilin Xie
Journal:  Inflammopharmacology       Date:  2017-02-25       Impact factor: 4.473

Review 5.  The effect of nutraceuticals on multiple signaling pathways in cardiac fibrosis injury and repair.

Authors:  Parinaz Zivarpour; Željko Reiner; Jamal Hallajzadeh; Liaosadat Mirsafaei; Zatollah Asemi
Journal:  Heart Fail Rev       Date:  2022-01       Impact factor: 4.214

6.  Thymoquinone Protects against Myocardial Ischemic Injury by Mitigating Oxidative Stress and Inflammation.

Authors:  Shreesh Ojha; Sheikh Azimullah; Rajesh Mohanraj; Charu Sharma; Javed Yasin; Dharamvir S Arya; Abdu Adem
Journal:  Evid Based Complement Alternat Med       Date:  2015-05-25       Impact factor: 2.629

7.  Telmisartan ameliorates insulin sensitivity by activating the AMPK/SIRT1 pathway in skeletal muscle of obese db/db mice.

Authors:  Asuka Shiota; Michio Shimabukuro; Daiju Fukuda; Takeshi Soeki; Hiromi Sato; Etsuko Uematsu; Yoichiro Hirata; Hirotsugu Kurobe; Norikazu Maeda; Hiroshi Sakaue; Hiroaki Masuzaki; Iichiro Shimomura; Masataka Sata
Journal:  Cardiovasc Diabetol       Date:  2012-11-08       Impact factor: 9.951

8.  Telmisartan protects against microvascular dysfunction during myocardial ischemia/reperfusion injury by activation of peroxisome proliferator-activated receptor γ.

Authors:  Xiao-Cong Zeng; Xing-San Li; Hong Wen
Journal:  BMC Cardiovasc Disord       Date:  2013-06-05       Impact factor: 2.298

9.  Telmisartan attenuates colon inflammation, oxidative perturbations and apoptosis in a rat model of experimental inflammatory bowel disease.

Authors:  Hany H Arab; Muhammad Y Al-Shorbagy; Dalaal M Abdallah; Noha N Nassar
Journal:  PLoS One       Date:  2014-05-15       Impact factor: 3.240

10.  Protective Effects of Cardamom in Isoproterenol-Induced Myocardial Infarction in Rats.

Authors:  Sameer N Goyal; Charu Sharma; Umesh B Mahajan; Chandragouda R Patil; Yogeeta O Agrawal; Santosh Kumari; Dharamvir Singh Arya; Shreesh Ojha
Journal:  Int J Mol Sci       Date:  2015-11-17       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.